No Data
Huazhao Zhongtian Pharmaceutical-B (02563.HK) has appointed Da Xin International (Hong Kong) as the new auditor.
On April 25, Gelonghui reported that Huahao Zhongtian Pharmaceutical-B (02563.HK) announced that the accounting firm KPMG has agreed to resign as the company's auditor at the request of the Board of Directors, effective April 24, 2025. Upon the recommendation of the Audit Committee, the Board of Directors has decided to propose the appointment of Shinewing International (Hong Kong) CPA Limited as the new auditor.
Huahao Zhongtian Pharmaceutical-B (02563): Tang Jin has been appointed as a member of the Audit Committee under the Board of Directors.
Huahao Zhongtian Pharmaceutical-B (02563) issued an announcement that due to the company's audit committee regarding Ms. Qi's situation since March 2025...
Huahao Zhongtian Pharmaceutical-B (02563.HK) will be suspended from trading starting April 1.
Gelonghui, April 1丨 Huahao Zhongtian Pharmaceutical-B (02563.HK) announced that since the company was unable to publish its 2024 annual results on or before March 31, 2025, it will apply for the suspension of its shares from trading on the Stock Exchange starting at 9:00 AM on April 1, 2025, pending the publication of the 2024 annual results.
BIOSTAR PHARM-B: DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS; AND POSSIBLE SUSPENSION OF TRADING
Huahao Zhongtian Pharmaceuticals-B (02563): Qi Jingyao resigns as Independent Non-Executive Director.
Hua Hao Zhong Tian Pharmaceutical-B (02563) announced that Ms. Qi Jingyao has resigned from the company as an independent director to focus on handling Other personal matters.
Huasheng Zhongtian Pharmaceutical-B (02563.HK) intends to hold a Board of Directors meeting on March 31 to approve the annual performance.
Gelonghui announced on March 17 that Huahao Zhongtian Pharmaceutical-B (02563.HK) will hold a Board of Directors meeting on March 31, 2025 (Monday) to (including) (i) consider and decide to approve the consolidated annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its publication; (ii) consider the proposal for the payment of a final dividend (if any); and (iii) address any Other matters.
